Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95
暂无分享,去创建一个
J. Rossi | R. Gressin | E. Deconinck | P. Colombat | O. Tournilhac | N. Milpied | C. Foussard | F. Maloisel | H. Eghbali | V. Lucas | T. Lamy | A. Thyss | J. Vilque | S. le Gouill | V. Delwail | B. Desablens | A. Simon | J. Jaubert | P. Casassus | M. Péoch
[1] N. Schmitz,et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Weisenburger,et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Horning,et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] P. Gascón,et al. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab , 2008 .
[5] C. Volteau,et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Briones,et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Horwitz. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. , 2008, Hematology. American Society of Hematology. Education Program.
[8] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[9] A. Zelenetz,et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma , 2007, British journal of haematology.
[10] S. Pileri,et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.
[11] R. Arranz,et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] S. Pileri,et al. Alemtuzumab ( Campath-1 H ) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma : results of a GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) prospective multicenter trial , 2007 .
[13] J. Delabie,et al. Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG). , 2006 .
[14] T. Barbui,et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.
[15] K. Savage. Aggressive peripheral T-cell lymphomas (specified and unspecified types). , 2005, Hematology. American Society of Hematology. Education Program.
[16] A. Chott,et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] D. Weisenburger,et al. Towards understanding the peripheral T-cell lymphomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] R. Gascoyne,et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Bates,et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.
[20] M. Boccadoro,et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Haim,et al. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin , 2004, Cancer Chemotherapy and Pharmacology.
[22] J. Delabie,et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas , 2001, Bone Marrow Transplantation.
[23] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[24] A. López-Guillermo,et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] S. Pileri,et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. , 1998, Blood.
[26] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[27] J. Bosq,et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease , 1998, Bone Marrow Transplantation.
[28] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[29] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[30] L. Bergmann,et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. , 1996, Leukemia & lymphoma.
[31] H. Stein,et al. Anaplastic large cell lymphoma Hodgkin's like , 1995 .
[32] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[33] P. Loehrer,et al. Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. , 1988, Medical and pediatric oncology.
[34] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[35] M. Oermann,et al. [Clinical evaluation]. , 1981, Ugeskrift for laeger.